HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 01/24/2013 -- Bristol-Myers Squibb Company (NYSE:BMY) climbed 2.4% or 85 cents to $35.75 after the biopharmaceutical reported total sales in the fourth quarter ending in December declined 23% to $4.19 billion from $5.45 billion in the same period of last year. Net earnings in the quarter jumped 9% to $925 million or 56 cents per diluted share compared to $852 million or 50 cents a share a year ago.
Can BMY Move Up Further? If Yes, How far It can Go? Find Out Here
Pfizer Inc. (NYSE:PFE) were up seven cents at $26.72 in recent premarket trading. Through Wednesday's close, the stock is up 23% in the past year. Pfizer Inc. is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition.
How Should Investors Trade PFE After The Recent Volatile Moves? Find Out Here
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares declined 2.60% and closed at $19.85 in the last trading session after the company has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by ARIAD. J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. are acting as joint book-running managers and underwriters for the proposed offering.
What Are ARIA’s Charts Signaling For Traders? Find Out Here
Generex Biotechnology Corporation (OTC:GNBT) increased 8.33% and closed at $0.0390 on a traded volume of 7.47 million shares. The Company has been advised by its Indian licensee, Shreya Life Sciences Pvt. Ltd that they have submitted a dossier of the results of the recently completed Phase III trial of Generex Oral-lyn to the Indian government seeking approval for marketing and commercial distribution. Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.
Has GNBT Found The Bottom And Ready To Gain Momentum? Find Out Here
Dendreon Corporation (NASDAQ:DNDN) decreased 3.14% and closed at $6.17 on a traded volume of 5.32 million shares. The median Wall Street price target on the stock is $6.0 and the high target is set at $18.00 with majority of analysts have a hold buy rating on the company’s stock. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $5.52 and $4.98 respectively.
Will New Regulations Weigh over DNDN Revenue Stream? Find Out Here
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)